Sanofi

Sanofi-A Ventis Deutschland Gmbh

Annika Hagendorf

Walter Kamm

Martina Kirsch

Ahmed Youssef

Dirk Usener

Sabrina Ruggeberg

Julia Schnieders

Christiane Fuerst

Werner Mueller

Verena Siefke-Henzler

Gerrit Hauck

Isabell Schoettle

Katrin Tertsch

Werner Muller

Werner Müller

The present invention provides stable pharmaceutical antibody formulations, including liquid drug product formulations and lyophilized drug product formulations, comprising an IgG4 binding agent and a citrate buffer, wherein the pH of the formulation is at or below both pH 6 and the pI of the binding agent. The formulations can be used in the treatment of chronic bowel diseases or rheumatoid arthritis.

Stable IGG4 based binding agent formulations

A liquid composition comprising a GLP-1 agonist or/and a pharmacologically tolerable salt thereof, an insulin or/and a pharmacologically tolerable salt thereof, and, optionally, at least one pharmaceutically acceptable excipient, wherein the composition comprises methionine, as add-on therapy with metformin where appropriate.

Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine

Stable IgG4 based binding agent formulations

Growing community of inventors

Hattersheim, Germany

Annika Hagendorf